Business Description
LB Pharmaceuticals Inc
NAICS : 541714
SIC : 2834
ISIN : US50180M1080
Total Employee Number:
27Description
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 62.83 | |||||
Equity-to-Asset | 0.92 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.06 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | N/A/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | -90.2 | |||||
3-Year EPS without NRI Growth Rate | -120.7 | |||||
3-Year FCF Growth Rate | -230 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | -8.55 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 49.32 | |||||
9-Day RSI | 62.05 | |||||
14-Day RSI | 65.56 | |||||
3-1 Month Momentum % | -0.19 | |||||
6-1 Month Momentum % | 38.17 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 15.08 | |||||
Quick Ratio | 15.08 | |||||
Cash Ratio | 13.91 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -4.1 | |||||
Shareholder Yield % | -6.85 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
ROE % | -35.15 | |||||
ROA % | -30.43 | |||||
ROIC % | -786.75 | |||||
3-Year ROIIC % | -212.6 | |||||
ROC (Joel Greenblatt) % | -1049.48 | |||||
ROCE % | -35.09 | |||||
Moat Score | 5 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PB Ratio | 3.82 | |||||
Price-to-Tangible-Book | 3.82 | |||||
EV-to-EBIT | -11.62 | |||||
EV-to-Forward-EBIT | -9.96 | |||||
EV-to-EBITDA | -11.66 | |||||
EV-to-FCF | -13.35 | |||||
| Price-to-Net-Current-Asset-Value | 3.9 | |||||
| Price-to-Net-Cash | 4.25 | |||||
Earnings Yield (Greenblatt) % | -8.61 | |||||
FCF Yield % | -5.8 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:LBRX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
LB Pharmaceuticals Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -3.44 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | - | ||
| 14-Day RSI | 65.56 | ||
| 14-Day ATR ($) | 2.73927 | ||
| 20-Day SMA ($) | 39.9845 | ||
| 12-1 Month Momentum % | - | ||
| 52-Week Range ($) | 13.36 - 49.14 | ||
| Shares Outstanding (Mil) | 32.26 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 9999 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
LB Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
LB Pharmaceuticals Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-30 | In 108 days | ||
| Second quarter earnings results for 2026 | 2026-08-31 | In 17 days | ||
| H.C. Wainwright 7(th) Annual Neuro Perspectives Hybrid Conference | 2026-06-16 | 28.50 (-0.18%) | ||
| Jefferies Global Healthcare Conference | 2026-06-04 14:35 | 27.95 (+3.44%) | ||
| General meeting for 2026 | 2026-06-03 09:30 | 27.02 (-2.28%) | ||
| First quarter earnings results for 2026 | 2026-05-12 | 32.70 (+2.20%) | ||
| 25th Annual Needham Virtual Healthcare Conference | 2026-04-16 11:45 | 29.12 (+10.34%) | ||
| Annual report for 2025 | 2026-03-26 | 24.21 (+2.93%) |
Show
Entries
LB Pharmaceuticals Inc Frequently Asked Questions
What is LB Pharmaceuticals Inc(LBRX)'s stock price today?
The current price of LBRX is $44.29. The 52 week high of LBRX is $49.14 and 52 week low is $13.36.
When is next earnings date of LB Pharmaceuticals Inc(LBRX)?
The next earnings date of LB Pharmaceuticals Inc(LBRX) is 2026-11-30 Est..
Does LB Pharmaceuticals Inc(LBRX) pay dividends? If so, how much?
LB Pharmaceuticals Inc(LBRX) does not pay dividend.
Guru Commentaries on NAS:LBRX
No articles.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Articles on LB Pharmaceuticals Inc
Is LB Pharmaceuticals Inc (LBRX) Facing Challenges After Q2 Earnings Miss? GF Score: 12/100
17 hours ago
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers